This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.
Steffi Oesterreich, PhD
Advertisement
Articles by Steffi Oesterreich, PhD
Advertisement
Latest Updated Articles
Combating Endocrine Resistance in Breast Cancer With Novel Agents, CombinationsPublished: January 12th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
3
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
4
Future of PCI: PCI vs MRI surveillance
5
